Can IBM’s Watson Help Cancer Patients?

Article

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a joint effort from the American Cancer Society and IBM that aims to use the cognitive power of Watson to help cancer patients deal with their disease.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a joint effort from the American Cancer Society and IBM that aims to use the cognitive power of Watson to offer cancer patients and survivors personalized guidance for their disease.

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content
Multiple Myeloma Experts Face Off on Sequencing Therapy Options

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

ONCOLOGY Staff
November 21st 2024
Article

Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MS
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

EU Approval Recommended for Repotrectinib in ROS1+ NSCLC, NTRK+ Solid Tumors

Roman Fabbricatore
November 20th 2024
Article

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Optimal Sequencing Between CAR T and Bispecifics in Multiple Myeloma

Optimal Sequencing Between CAR T and Bispecifics in Multiple Myeloma

ONCOLOGY Staff
November 20th 2024
Article

The use of CAR T-cell therapy and other sequencing options were discussed for patients with multiple myeloma.

Discerning the Best Frontline, Personalized Treatment in Urothelial Carcinoma

Discerning the Best Frontline, Personalized Treatment in Urothelial Carcinoma

Alex Biese
November 20th 2024
Article

“How do we personalize and improve patient selection for frontline treatment now that patients are living, on average, more than 2 years with this aggressive cancer?” said David H. Aggen, MD, PhD